Latest Breaking News On - Fetal toxicity - Page 16 : comparemela.com

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations. This analysis shows a clinically meaningful improvement in progression-free survival across the subgroups studied, including those patients with bone, liver and/or lung metastases, those with common […]

United statesMenarini stemlineElcin barker ergunMenarini industrie farmaceutiche riuniteMenarini group stemline therapeuticMd anderson cancer centerElacestrant clinical development programMenarini groupStemline therapeutics incUt health san antonioStemline therapeuticsAntonio breast cancer symposiumVirginia kaklamaniSan antonioSafety informationStemline therapeutic

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

/PRNewswire/ Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved.

United statesStevens johnsonAntonioc arrietaMark reisenauerLynn fenicchiaDrug administrationPrnewswire astellas pharma us incBasilea pharmaceutica international ltdAstellas pharma us incChildren health of orangeAstellas pharma incPediatric infectious diseaseSpecialties business unitMedical mycologyInvasive aspergillosisSafety information

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesLynn fenicchiaStevens johnsonAntonioc arrietaMark reisenauerAstellas pharma us incChildren health of orangeDrug administrationAstellas pharma incBasilea pharmaceutica international ltdPrnewswire astellas pharma us incPediatric infectious diseaseSpecialties business unitMedical mycologyInvasive aspergillosisSafety information

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter dannenbaumDamini chokshiJulie cunninghamExchange commissionMerck research laboratoriesStatement of merck co incData monitoring committeeMerck co incMarjorie greenMerck researchResponse evaluation criteriaSolid tumorsInduction phaseMaintenance phaseSelected important safety

Gilead Sciences: Gilead s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

Gilead Sciences: Gilead s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFoster cityStefan klotterSacituzumab govitecanGilead sciences incGilead sciencesNational comprehensive cancer network incExchange commissionNational comprehensive cancer networkEuropean unionGilead public affairsSan antonio breast cancer symposiumBill grossmanSenior vice presidentTherapeutic area headAccepted abstracts